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Yuan-Yuan Xie,a† Zidong Lu,b† Xiao-Le Kong,b Tao Zhou,c Sukhi Bansal,b Robert 
Hiderb 
a
 College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, 
China  
b
 Institute of Pharmaceutical Science, King’s College London, UK  
c
 School of Food Science and Biotechnology, Zhejiang Gongshang University, 
Hangzhou, China. 
†
 Joint first authors. 
Abstract  
A range of close analogues of deferiprone have been synthesised. The group includes 
mono-, di- and tri-methyl-3-hydroxy-4(1H)-pyridones. These compounds were 
found to possess similar pFe3+ values to that of deferiprone, with the exception of the 
2.5-dimethylated derivatives. Surprisingly the NH-containing 
hydroxy-4(1H)-pyridones were found to be marginally more lipophilic than the 
corresponding N-Me containing analogues. This same group are also metabolised 
less efficiently by Phase 1 hydroxylating enzymes than the corresponding N-Me 
analogues. 
As result of this study, three compounds have been identified for further 
investigation centred on neutropenia and agranulocytosis. 
 
Corresponding author:  
E-mail address: robert.hider@kcl.ac.uk 
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Highlights: 
 Mono-, di- and trimethyl 3-hydroxy-4(1H)-pyridones possess very similar pFe3+ 
values. 
 N-methyl-3-hydroxy-4(1H)-pyridones are less lipophilic than corresponding 
NH- compounds. 
 N-methyl-4(1H)-pyridones are metabolised faster than corresponding NH- 
compounds. 
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Graphic Abstract 
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1.  Introduction 
Deferiprone (1) is a useful iron-selective chelator which is widely used to treat 
systemic iron overload associated with regular blood transfusion.[1,2] It is 
particularly effective at removing iron from the iron-overloaded heart.[3,4] The free 
ligand readily enters cells by non facilitated diffusion and the resulting iron complex, 
by virtue of lacking a charge and possessing a molecular weight of less than 500 is 
able to efflux from cells, leading to enhanced renal excretion of iron.[5] Deferiprone 
(1) has a low affinity for iron(II) and does not disturb the normal cytosolic labile iron 
pool.[6] However deferiprone has two disadvantages, namely rapid metabolism[7] 
and initiation of reversible agranulocytosis in approximately 1% of patients 
receiving the drug.[8] Metabolism leads to glucuronidation of the 3-hydroxyl 
function,[7] thereby removing the chelating ability of the molecule. This property 
leads to relatively high doses of deferiprone being adopted in the clinic, typically 
75-100 mg/kg.[9] 
There have been several attempts to modify the 3-hydroxy-4(1H)-pyridone structure, 
while maintaining the same high affinity for iron(III) and limiting the molecular 
weight of the corresponding iron(III) complex to less than 500. Thus the introduction 
of an additional nitrogen into the ring leading to the 3-hydroxypyridazin-4-one (2) 
and 5-hydroxypyridazin-4-one (3) groups has been investigated.[10] However the 
introduction of the additional nitrogen, leads to a marked reduction in the affinity for 
iron(III); the pFe3+ values being 20.6, 14.8, 17.2 for 1, 2 and 3 respectively.[10] In 
order to successfully scavenge iron from iron overloaded tissues, a minimum pFe3+ 
value of 20 is required.[5] The introduction of fluorine into the hydroxypyridinone 
structure has been investigated.[11] However the presence of the fluorine was also 
found to reduce the pFe3+ values when compared with that of deferiprone, thus 4, 5 
and 6 have values of 19.4, 17.8 and 18.9 respectively.[12] 
In a further attempt to optimize, the logP and pFe3+ values of 
3-hydroxy-4(1H)-pyridone, together with the rate of metabolism, a range of 
monomethyl, dimethyl and trimethyl analogues of deferiprone (7-10) have been 
investigated, the results of which are reported in this communication. 
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2. Chemistry 
2.1 Synthesis 
The synthesis of four of the deferiprone analogues was achieved using previously 
published methods; namely 7,[13] 9a,[7] 10a[14] and 10b.[15] Scheme 1 illustrates 
the synthetic route employed for the preparation of 8a and 8b starting from 
commercially available kojic acid (11). Protection of the 3-hydroxyl group was 
achieved by methylation using dimethyl sulfate or benzylation using benzylchloride, 
both under basic conditions. The hydroxymethyl function was oxidised to a 
carboxylic acid, which was subsequently decarboxylated by heating in 
1-methyl-2-pyrrolidinone to yield the protected pyrones 14a and 14b. The ring 
oxygen was replaced by nitrogen via reaction with aqueous ammonia and the 
resulting 4(1H)-pyridones were subjected to a Mannich reaction with dimethylamine 
to yield the 4(1H)-pyridones 16a and 16b. Reduction of 16b yielded 8b and 
reduction of 16a yielded 17, which on methylation and subsequent treatment with 
BBr3 yielded 8a. The preparation of 9b was also initiated using kojic acid, which 
was converted to the 6-methyl-4(1H)-pyridone in a step wise manner (Scheme 2) 
3. Results and discussion 
3.1 Physicochemical Characterisation. 
The pKa and logKeq(Fe3+) values were investigated using an automated 
spectrophotometric titration system. The UV profile of 8b over the pH range 
1.6-11.0 (Figure 1A) on analysis yielded two pKa values, namely 3.31 (carbonyl) 
and 9.49 (phenol). When the titration was repeated in the presence of iron(III), over 
the pH range 1.2-8.0, the visible profile was indicative of three species, FeL, FeL2 
and FeL3 (Figure 1B). Resolution of the spectra of these three species led to the 
determination of the corresponding three equilibrium constants, namely; logK1 = 
14.41, logβ2 = 26.31 and logβ3 =35.80. A speciation plot based on these values is 
presented in figure 1C. It is clear that under most invivo conditions, where 8b would 
be present in excess of labile iron, the dominant species is the neutral FeL3 complex. 
Analogous titrations for the other hydroxypyridinones reported in this study are 
presented in the Supplementary Data. All the determined pKa values and affinity 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 6
constants for iron(III) are presented in Table 1. The pFe3+ value for 8b was 
calculated to be 20.06. The mean pFe3+ value of the 4 N-methyl compounds, 20.3, is 
marginally higher than the mean pFe3+ values of the 4 N-H compounds, namely 19.9. 
The pFe3+ values of the two 2,5-dimethyl derivatives are the lowest in the series. 
All the ligands investigated were found to be hydrophilic (Table 1). The resulting 
neutral iron(III) complexes were also hydrophilic. The overall relationship between 
ligands and iron complexes being linear, with a slope of 2.25 (Figure 2); that is the 
iron complexes are more hydrophilic than the free ligands. This a similar result to 
that of a more extensive study of hydroxypyridinones.[16] On comparison of the 
analogous pairs, namely 1/7; 8a/8b; 9a/9b and 10a/10b, without exception, the 
N-H-containing compounds were found to be less hydrophilic than the 
N-Me-containing compounds. The same difference occurs with the iron(III) 
complexes. This is surprising because the N-methyl compounds all contain one more 
sp3 carbon atom than the N-H compounds and the N-H compounds all possess a 
larger hydrophilic surface area. Both these differences suggest that the N-H 
compounds of each analogous pair would be more hydrophilic than the 
corresponding N-Me compounds, which contradicts the observed logP values. This 
entire group of molecules have two mesomeric forms (22 and 23) and the percentage 
contribution of each form will influence the oil/water partitioning properties, the 
aromatic mesomer (23) being zwitterionic. Using DFT simulation[17] we have 
determined the percentage contribution of each mesomeric form, in vacuo and in a 
simulated aqueous environment, for the four pyridinone pairs. There is a constantly 
lower contribution from the zwitterionic mesomer of the NH compounds when 
compared with the corresponding NMe compounds for calculations undertaken both 
in the presence of water and in vacuo (Figure 3). However this difference is small, 
for instance in the presence of water the average zwitterionic contribution is 31.5 ± 
0.7% for the four N-Me compounds and 30.6 ± 0.7% for the four N-H compound. It 
is unclear whether this difference is suffient to explain the differences in partition 
coefficients; namely mean logP value for the 4 N-methyl compounds is -0.85, 
whereas the corresponding value for the N-H compounds is -0.51. In a further 
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attempt to identify the cause of this difference in partitioning behavior, the 
possibility of dimer formation via aromatic π – π interaction between two 
hydroxypyridinone molecules was considered. It is established that pyridine-pyridine 
dimers form parallel-displaced configurations.[18] The zwitterionic nature of the 
hydroxy-4(1H)-pyridones could favor a similar dimer configuration. Indeed, the 
presence of a dimer was detected by MS where at 140 µM the ratio of peak heights 
of the monomer (140.17) and dimer (279.0) for deferiprone (1) was 1.12 (Figure 4). 
In contrast, at the same concentration, the pyridinone 7 only gave a weak dimer peak 
(251) when compared with the monomer peak (126), the ratio being 0.11. The 
presence of the dimer is strongly concentration dependent (Figure 5). Thus there is a 
clear difference in behavior between the N-Me and N-H derivatives with respect to 
the tendency of dimer formation. However the determined logP values 
(water/octanol) of deferiprone over the concentration range 200 µM – 10 µM did not 
change, indicating that the tendency for dimer formation did not influence the 
partitioning properties of the chelators. 
Thus in summary the highest pFe3+ values of the entire group is associated with 
deferiprone (1), although the values for 8a and 9a are quite close and in excess of 20. 
The lowest pFe3+ values are associated with (10a) and (10b), this resulting from the 
markedly higher pKa2 values than the rest of the group. As indicated above, the logP 
values of the free ligands are higher for the NH-containing group, 7 having the 
highest value of those pyridinones with pFe values greater than 20.  
3.2 Metabolism of 3-Hydroxy-4(1H)-pyridones 
The metabolism of this group of hydroxypyridinones was assessed using human 
liver microsomes; both phase 1 and phase 2 reactions being monitored. The phase 1 
metabolites were characterised by mass spectroscopy. It was not possible to study 9b 
using this technique due to complications with dimerisation of the free ligand. The 
extent of glucuronidation (Phase 2) was found to be similar throughout the entire 
series (Figure 6). Phase 1 metabolism, was established to be hydroxylation, in 
agreement with earlier studies.[7,19] 7 and 8b were found to hydroxylated to a less 
extent than deferiprone (1), indeed all the (N-H)pyridinones were hydroxylated at a 
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lower rate than the corresponding (N-Me)pyridinones. 
4. Conclusion 
Despite its success in the treatment of thalassaemia, deferiprone, suffers from 
extensive metabolism[7] and the initiation of reversible agranulocytosis.[8] 
Consequently a replacement candidate is required; introduction of either an 
additional nitrogen in the ring or a fluorine substituent was found to reduce the pFe3+ 
value, which is a critically important parameter for efficient iron scavenging. As 
deferiprone possesses many ideal properties for the removal of excess iron in 
biological tissues, in the present study we decided to systematically investigate the 
properties of a range of close structural analogues. The comparison of pKa, pFe and 
logP values, together with metabolic profiles, identified several new features of these 
molecules. Although none of the seven analogues bind iron(III) as tightly as 
deferiprone, five of them possess pFe3+ values > 20, in marked contrast to other 
close analogues, recently investigated.[10-12] The substitution of the 1-methyl 
substituent with hydrogen had two beneficial effects, an enhanced logP value and a 
reduced tendency for phase 1 metabolism. The enhanced logP value is surprising, 
and remains unexplained at the present time. The critical physicochemical 
parameters of the three analogues with potential for clinical application, namely 7, 
8b and 9b, are pFe3+, 20.17, 20.06 and 20.13 respectively and logP, -0.58, -0.59 and 
-0.73 respectively. All three are metabolised more slowly than deferiprone via the 
phase 1 route. Although only marginally different to the corresponding values for 
deferiprone, it will be appropriate to test these three molecules in the mouse for their 
ability to induce neutropenia and agranulocytosis, the most important side effect of 
deferiprone. 
5. Experimental Section 
5.1 Syntheses. 
All starting materials were obtained from commercial sources and used without 
further purification. 5-Hydroxy-2-(hydroxymethyl)-4H-pyran-4-one (kojic acid, 11) 
was purchased from Fluka. The synthesis of four of the hydroxypyridin-4-ones was 
achieved using previously published methods, namely 7,[13] 9a[7] and 10a[14] and 
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10b.[15] The purity of the eight hydroxypyridinones 7, 8a, 8b, 9a, 9b, 10a and 10b 
were all assessed by reversed phase HPLC and all were found to possess a purity of 
greater than 98%. 
5.1.1 2-Hydroxymethyl-5-methoxy-4H-pyran-4-one (12a)  
Kojic acid ，?11，? (126.00 g, 887 mmol) was dissolved in 10% potassium hydroxide 
solution (620 mL) and cooled to 10oC. Then dimethyl sulfate was added dropwise 
over 30min. The reaction mixture was stirred at 10 oC for 1h. The precipitate was 
collected by filtration and washed with acetone to give a white solid (12a) (104.3 g, 
75%). 1H NMR (400 MHz, DMSO-d6) δ: 8.08 (s, 1H), 6.29 (s, 1H), 5.70 (t, J=6.0Hz, 
1H), 4.29 (d, J=6.0Hz, 2H), 3.64 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ: 172.9, 
168.1, 148.0, 139.0, 110.8, 59.4, 56.2. 
5.1.2 5-Methoxy-4-oxo-4H-pyran-2-carboxylic acid (13a)  
2-Hydroxymethyl-5-methoxy-4H-pyran-4-one (12a) (6.24 g, 40 mmol) was refluxed 
in acetone (600 mL). Jones-reagent (33 mL) was added to the solution and the 
reaction mixture was refluxed for 40min. The reaction mixture was cooled to room 
temperature. The precipitate was collected by filtration and washed with water to 
give a white solid (13a) (4.95 g, 73%). 1H NMR (400 MHz, DMSO-d6) δ: 8.27 (s, 
1H), 6.90 (s, 1H), 3.69 (s, 3H), 3.37 (br, 1H); 13C NMR (100 MHz, DMSO-d6) δ: 
172.7, 160.9, 152.5, 149.4, 139.6, 116.7, 56.3. 
5.1.3 3-Methoxy-4H-pyran-4-one (14a)  
5-Methoxy-4-oxo-4H-pyran-2-carboxylic acid (13a) (34.00 g, 200 mmol) and 
1-methyl-2- pyrrolidinone (500 mL) were refluxed for 4h. The solvent was removed 
azeotropically with N,N-dimethylformamide (500 mL) in high vacuum. The residue 
was extracted into dichloromethane and washed with 5% aqueous sodium hydroxide 
(3×270 mL). The organic layer was dried over Na2SO4, concentrated and 
recrystallized from toluene to give the yellow solid (14a) (11.32 g, 45%). 1H NMR 
(400 MHz, DMSO-d6) δ: 8.12 (s, 1H), 8.10 (d, J=5.2Hz, 1H), 6.35 (d, J=5.2Hz, 1H), 
3.65 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ: 172.3, 155.7, 148.8, 139.8, 115.4, 
56.1. 
5.1.4 3-Methoxy-4(1H)-pyridone (15a) 
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3-Methoxy-4H-pyran-4-one (14a) (3.78 g, 30 mmol) and 30% ammonia solution (40 
mL, 300 mmol) were heated at 70oC in 50% ethanol-water solution (50 mL) for 8h. 
The reaction mixture was concentrated to give product (15a) (3.48 g, 94%). 1H NMR 
(400 MHz, DMSO-d6) δ: 7.57 (d, J=6.4Hz, 1H), 7.47 (s, 1H), 6.17 (d, J=6.4Hz, 1H), 
3.66 (s, 3H). 
5.1.5 3-((Dimethylamino)methyl)-5-methoxy-4(1H)-pyridone (16a)  
3-Methoxy-4(1H)-pyridone (15a) (3.13 g, 25 mmol), 40% formaldehyde (3.75 g, 50 
mmol) and 40% dimethylamine (11.25 g, 100 mmol) were refluxed in ethanol (120 
mL) for 72h. Then the reaction mixture was concentrated and the crude product was 
recrystallized from acetone/ethanol to give a white solid (16a) (3.52 g, 77%). 1H 
NMR (400 MHz, DMSO-d6) δ: 7.53 (s, 1H), 7.45 (s, 1H), 3.66 (s, 3H), 3.25 (s, 2H), 
2.14 (s, 6H) ; 13C NMR (100 MHz, DMSO-d6) δ: 164.5, 148.1, 134.7, 122.6, 120.7, 
56.0, 55.0, 44.9. 
5.1.6 3-Methoxy-5-methyl-4(1H)-pyridone (17)  
To 3-((dimethylamino)methyl)-5-methoxy-4(1H)-pyridone (16a) (1.46 g, 8 mmol), 
dissolved in absolute ethanol (60 mL) and cyclohexene (80 mL), palladium 
hydroxide on carbon (2 g) was added. The reaction mixture was refluxed for 5 days 
with further additions of cyclohexene (80 mL) and palladium hydroxide on carbon (4 
g) at intervals. On cooling, the precipitate was filtered off and the filtrate was 
concentrated and purified by column chromatography on silica gel (eluent: 
CH3OH/CH2Cl2 1:8) to give a white solid (17) (0.91 g, 81%).1H NMR (400 MHz, 
CDCl3) δ: 7.60 (s, 1H), 7.45 (s, 1H), 3.78 (s, 3H), 2.14 (s, 3H) ; 13C NMR (100 MHz, 
CDCl3) δ: 171.3, 148.4, 134.0, 123.7, 119.1, 56.2, 13.9. 
5.1.7 3-Methoxy-1,5-dimethyl-4(1H)-pyridone (18)  
To 3-methoxy-5-methyl-4(1H)-pyridone (17) (0.70 g, 5 mmol), dissolved in MeOH 
(20 mL), K2CO3 (0.76 g, 5.5 mmol) was added at room temperature and, 15min later, 
iodomethane (0.85 g, 6 mmol) was added. Then the reaction mixture was stirred at 
room temperature overnight. After completion, the reaction mixture was 
concentrated and the residue was purified by column chromatography on silica gel 
(eluent: CH3OH/CH2Cl2 1:6) to give a white solid (18) (0.68 g, 88%). 1H NMR (400 
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MHz, CDCl3) δ: 7.13 (d, J=1.2Hz, 1H), 6.92 (d, J=2.0Hz, 1H), 3.76 (d, J=1.2Hz, 
3H), 3.66 (s, 3H), 2.05 (s, 3H); 13C NMR (100 MHz, CDCl3) δ: 171.4, 148.6, 135.8, 
124.7, 121.8, 56.3, 44.0, 13.8; ESI-MS m/z 154 (M+H)+. 
5.1.8 3-Hydroxy-1,5-dimethyl-4(1H)-pyridone hydrobromide (8a)  
3-Methoxy-1,5-dimethyl-4(1H)-pyridone (18) (0.38 g, 2.5 mmol) was dissolved in 
CH2Cl2 (15 mL) and flushed with nitrogen. After the flask was cooled to 0 °C, 
tribromoborane (1M in CH2Cl2, 10 mL) was slowly added, and the reaction mixture 
was allowed to stir at room temperature for 12 h. The excess BBr3 was eliminated at 
the end of the reaction by the addition of methanol (15 mL) and left to stir for 
another 0.5 h. After removel of the solvents under reduced pressure, the residues 
were purified by recrystallization from methanol/ether to afford a white solid, mp = 
228oC with decomposition, (0.34 g, 62%). 1H NMR (400 MHz, DMSO-d6) δ: 8.26 (s, 
1H), 8.06 (d, J=2.0Hz, 1H), 4.04 (s, 3H), 3.57 (br, 2H), 2.17 (s, 3H) ; 13C NMR (100 
MHz, DMSO-d6) δ: 158.0, 143.8, 138.7, 129.3, 123.2, 45.9, 12.8; ESI-MS m/z calc. 
for C7H10NO2 (M+H)+ 140.0706, found 140.0702. 
5.1.9 5-Benzyloxy-2-hydroxymethyl-4H-pyran-4-one (12b)  
Kojic acid (11) (14.20 g, 100 mmol) was dissolved in methanol (100 mL), and 
sodium hydroxide (4.40 g, 110 mmol) in water (10 mL) was added. The reaction 
mixture was heated to reflux. Then benzyl chloride (13.92 g, 110 mmol) was added 
dropwise over 30min and refluxed for 18h. The reaction mixture was concentrated, 
and dichloromethane (400 mL) was added to the residue. The inorganic salt was 
filtered off. The dichloromethane was washed with 5% sodium hydroxide solution 
(100 mL), water (100 mL), dried over Na2SO4, filtered, concentrated and 
recrystallized from ethanol to give a pale yellow solid (12b) (19.26 g, 83%). 
5.1.10 5-Benzyloxy-4-oxo-4H-pyran-2-carboxylic acid (13b)  
5-Benzyloxy-2-hydroxymethyl-4H-pyran-4-one (12b) (10.00 g, 43 mmol) was 
dissolved in acetone (1000 mL). Jones-reagent (25 mL) was added to the solution 
and the reaction mixture was stirred below 20oC for 3h. The precipitate was filtered 
off. The filtrate was concentrated to dryness and the crude product was recrystallized 
from methanol to give white crystals (13b) (8.51 g, 80%). 
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5.1.11 3-Benzyloxy-4H-pyran-4-one (14b)  
5-Benzyloxy-4-oxo-4H-pyran-2-carboxylic acid (13b) (15.87 g, 64.5 mmol) and 
1-methyl-2- pyrrolidinone (160 mL) were refluxed for 4h. Then the solvent was 
removed azeotropically with N,N-dimethylformamide (160 mL) in high vacuum. The 
residue was extracted into dichloromethane and washed with 5% aqueous sodium 
hydroxide (3×90 mL). The organic layer was dried over Na2SO4, concentrated and 
recrystallized from toluene to give a pale yellow solid (14b) (9.07 g, 70%). 
5.1.12 3-Benzyloxy-4(1H)-pyridone (15b) 
3-Benzyloxy-4H-pyran-4-one (14b) (7.90 g, 39 mmol) and 30% ammonia solution 
(52 mL, 390 mmol) were heated at 70oC in 50% ethanol-water solutuion (60 mL) for 
24h. Then the reaction mixture was cooled to room temperature. The precipitate was 
collected by filtration to give a white solid (15b) (6.98 g, 89%). 
5.1.13 3-Benzyloxy-5-((dimethylamino)methyl)-4(1H)-pyridone (16b)  
3-Benzyloxy-4(1H)-pyridone (15b) (3.02 g, 15 mmol), 40% formaldehyde (2.25 g, 
30 mmol) and 40% dimethylamine (6.75 g, 60 mmol) were refluxed in ethanol (100 
mL) for 72h. Then the reaction mixture was concentrated and the crude product was 
recrystallized from acetone/ethanol to give a white solid (16b) (2.76 g, 71%). 1H 
NMR (400 MHz, DMSO-d6) δ: 7.52-7.50 (m, 2H), 7.42-7.35 (m, 5H), 5.00 (s, 2H), 
3.23 (s, 2H), 2.14 (s, 6H); 13C NMR (100 MHz, DMSO-d6) δ: 169.8, 146.7, 137.3, 
134.9, 128.4, 128.0, 127.9, 123.8, 123.6, 70.5, 55.1, 45.0. 
5.1.14 3-Hydroxy-5-methyl-4(1H)-pyridone hydrochloride (8b) 
To 3-benzyloxy-5-((dimethylamino)methyl)-4(1H)-pyridone (16b) (1.00 g, 3.9 
mmol), dissolved in absolute ethanol (30 mL) and cyclohexene (40 mL), palladium 
hydroxide on carbon (1 g) was added. The reaction mixture was refluxed for 5 days 
with further additions of cyclohexene (40 mL) and palladium hydroxide on carbon (2 
g) at intervals and then cooled. The catalysts were filtered off. The filtrate was 
acidified with hydrochloric acid, concentrated and purified by column 
chromatography on silica gel (eluent: CH3OH/CH2Cl2 1:7) to give a white solid, mp 
= 237-238oC (8b) (0.47 g, 75%).1H NMR (400 MHz, DMSO-d6) δ: 8.13 (s, 1H), 
8.07 (s, 1H), 2.18 (s, 3H) ; 13C NMR (100 MHz, DMSO-d6) δ: 170.7, 145.8, 131.8, 
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120.4, 117.2, 13.2; ESI-MS m/z calc. for C6H8NO2 [M+H]+ 126.0550, found 
126.0552. 
5.1.15 5-Hydroxy-2-methyl-4H-pyran-4-one (20a) was synthesized from kojic acid 
in two steps using a previously published procedure.[20] 
5.1.16 5-Benzyloxy-2-methyl-4H-pyran-4-one (20b)  
5-Hydroxy-2-methyl-4H-pyran-4-one (20a) (3.78 g, 30 mmol) was dissolved in 
methanol (30 mL), and sodium hydroxide (1.32 g, 33 mmol) in water (3 mL) was 
added. The reaction mixture was heated to reflux. Then benzyl chloride (4.18 g, 33 
mmol) was added dropwise and refluxed for 4h. The reaction mixture was 
concentrated, and dichloromethane (150 mL) was added to the residue. The 
inorganic salt was filtered off. The dichloromethane was washed with 5% sodium 
hydroxide solution (30×2 mL), water (30 mL), dried over Na2SO4, filtered, 
concentrated and recrystallized from dichloromethane/petroleum ether to give a 
white solid (20b) (5.25 g, 81%). 1H NMR (400 MHz, CDCl3) δ: 7.46 (s, 1H), 
7.41-7.32 (m, 5H), 6.21 (s, 1H), 5.07 (s, 2H), 2.31 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ: 174.8, 165.0, 146.7, 141.6, 135.9, 128.6, 128.3, 127.8, 114.3, 71.8, 19.6. 
5.1.17 5-Benzyloxy-2-methyl-4(1H)-pyridone (21)  
5-Benzyloxy-2-methyl-4H-pyran-4-one (20b) (4.32 g, 20 mmol) and 30% ammonia 
solution (26 mL, 200 mmol) were heated at 70oC in 50% ethanol-water solution (30 
mL) for 48h. Then the reaction mixture was cooled to room temperature. The 
precipitate was collected by filtration to give a white solid (21) (4.02 g, 93%). 1H 
NMR (400 MHz, DMSO-d6) δ: 11.21 (br, 1H), 7.9-7.31 (m, 6H), 6.00 (s, 1H), 4.97 
(s, 2H), 2.16 (s, 3H); ESI-MS m/z 216 [M+H]+. 
5.1.18 5-Hydroxy-2-methyl-4(1H)-pyridone hydrochloride (9b) 
Palladium (5%) on carbon (0.12 g) was added to the solution of 
5-benzyloxy-2-methylpyridin-4(1H)-one (21) (1.08 g, 5 mmol) in methanol (20 mL). 
The reaction mixture was subjected to hydrogenolysis for 3.5h. The catalysts were 
filtered off. The filtrate was acidified with concentrated hydrochloride acid, 
concentrated and recrystallized from methanol/diethyl ether to give a white solid, mp 
= 183-184oC (9b) (0.73g, 90%). 1H NMR (400 MHz, DMSO-d6) δ: 8.00 (s, 1H), 
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7.12 (s, 1H), 2.48 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ: 161.0, 145.9, 143.4, 
125.8, 112.4, 18.2; ESI-MS m/z calc. for C6H8NO2 [M+H]+ 126.0550, found 
126.0548. 
5.2 Physical Measurements  
1H NMR spectra were recorded using a Bruker 360 MHz NMR spectrometer. 
Chemical shifts are reported in ppm. 
Mass spectra (ESI) analyses were carried out by the Mass Spectrometry Facility, 
School of Biomedical Sciences, 150 Stamford Street London, SE1 9NH, U.K. 
For pKa determinations, an automatic titration system comprising an autoburet 
(Metrohm Dosimat 765, 1 mL syringe) and a Mettler Toledo MP230 pH meter with a 
Metrohm pH electrode (6.0133.100) and a reference electrode (6.0733.100) was used. 
A 0.1 M KCl electrolyte solution was used to maintain the ionic strength. For the 
measurements the temperature of the probe solution was maintained in a 
thermostatic jacketed titration vessel at 2.5 ± 0.1 oC using a Teghne TE-8J 
temperature controller. The solution was stirred vigorously during the experiment. A 
Gilson Mini-plus#3 pump with speed capability (20 mL/min) was used to circulate 
the probe solution through a Hellem quartz flow cuvette. A cuvette path length of 10 
mm was used and the flow cuvette mounted on a HP 8453 UV – visible 
spectrophotometer. All instruments were interfaced to a computer and controlled by 
a Visual Basic program. The pH of the probe solution was increased by 0.1 pH unit 
by the addition of KOH from the autoburet. When pH readings varied by <0.001 pH 
unit over a 3 s period, an incubation period of 1 min was adopted. At the end of the 
equilibrium period, the spectrum of the solution was recorded. The cycle was 
repeated automatically until the defined end point pH value was achieved. Titration 
data were analyzed by pHab.[21] 
5.2.1 pKa Determination.  
The pH electrodes were calibrated by titrating a volumetric standard strong acid HCl 
(0.15 mL, 0.2092 M) in KCl (15 mL, 0.1 M) with KOH (0.1 M) under an argon 
atmosphere at 25 oC. The E0, slope of the electrode, and pKw of the solution were 
both optimized by GLEE.[22] Following electrode calibration, a 1 mM solution of 
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ligand in 00.162 mL of 0.1 M KCl at an initial pH value of 1.646 were 
alkalimetrically titrated to pH 11.162. The spectra of the ligands and the titration 
experimental data at different pH values were analyzed by refining the extinction 
coefficients of the protonated and deprotonated species. 
5.2.2 Fe3+ Stability Constant Determination.  
For the stability constant determinations, a 50mm path length cuvette was used. 
Automatic titration and spectral scans adopted the following strategy: the pH of a 
solution was increased by 0.1 pH unit by the addition of KOH from the autoburette; 
when pH readings varied by <0.001 pH unit over a 3s period, an incubation period 
was activated. For stability constant determinations, a period of 5 min was adopted. 
At the end of the equilibrium period, the spectrum of the solution was recorded. The 
cycle was repeated automatically until the defined end point pH value was achieved. 
All the titration data were analyzed with the pHab program.[21] The species plot was 
calculated with the HYSS program.[22] Analytical grade reagent materials were used 
in the preparation of al solutions. pFe3+ conditions were [Fe3+]Total = 1 µM; 
[Ligand]Total = 10 µM, pH = 7.4. 
5.2.3 LogP Determination.  
The logP values of both the ligands and the corresponding 1:3 complexes were 
determined by the shake-flask method using a n-octanol-aqueous system at 25oC. 
Because the logP is strictly defined for neutral molecules, the partition studies were 
undertaken in MOPS (25 mM, pH 7.4). The absorbance of a buffered probe solution 
of known concentration was recorded spectrophotometrically, and different ratios of 
buffered probe solution and n-octanol were then shaken by vigorous stirring for 15 
sec. The layers were subsequently separated by centrifugation at 25oC. The aqueous 
phases were again measured spectrophotometrically showing a decrease of probe 
absorbance due to partition into the organic phase. Lipophilicity, directly correlating 
with the detected decrease in probe absorbance, was derived from the recorded UV 
spectra according to the following equation: 
 
P  =                               
(A0-A1)Vaq 
A1Vo 
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Where A0 is the initial absorbance of the aqueous phase, A1 is the absorbance of the 
aqueous phase after partition. 
5.3 Metabolism of 3-hydroxypyridin-4-ones  
Individual hydroxypyridinones (10 µM) were incubated with 1mg/mL UltraPool™ 
Human Liver Microsome (HLM) 150 Mixed Gender Pooled, Cat No. 452117 
(Corning Ltd-Life Sciences, Ewole, UK) with the add-in of Phase I or Phase I&II 
Corning NADPH and UDPGA system solutions (Corning Ltd-Life Sciences, Ewloe, 
UK)) in 100mM PBS buffer. NADPH regenerating system solution A (Cat No. 
451220, Lot No. 3189637), NADPH regenerating system solution B (Cat No. 
451200, Lot No. 3246566), UGT reaction mix solution A (UDPGA Cofactor) (Cat 
No. 451300, Lot No. 3211810), UGT reaction mix solution B (5X-UGT Buffer Mix 
with Alamethicin) (Cat No. 451320, Lot No. 3211815). Blanks were prepared the 
same way except that HLM was excluded in incubates. 500µL incubation solutions 
were prepared with one single blank and triplicate sample solutions for each HPO 
compound. Solutions were incubated at 37°C in for 24hrs with gentle shaking to 
prevent protein sedimentation. The reactions were terminated by spiking in 400µL 
4% phosphoric acid, followed by spiking in 100µL of 100µM CP21 as the internal 
standard. Samples were mixed evenly by the vortex mixer and followed by 
centrifuge at 14,000 rpm in a Spectrafuge™ 16M microcentrifuge (Labnet 
International Inc., NJ, USA) for 10min. The supernatants were collected for the 
further solid phase extraction.  OASIS MCX (Mixed-Mode Cation-exchange) 
96-well µElution Plate, 2 mg sorbent per well, 30 µm Particle Size (Oasis®, Waters, 
UK) was applied to extract the parent HPO compounds and their metabolites with a 
high throughput Supelco® SPE PlatePrep vacuum manifold (Sigma-Aldrich, UK).  
Sample plates after SPE were subjected to a Waters Acquaity UPLC- XevoTM TQ 
MS system (Waters Limited, Elstree, UK) to further identify the major metabolites 
and quantify the percentage of drug metabolized after 24hrs incubation. The Agilent 
Poroshell 120 EC-C18 column, 2.1 x 50mm 2.7µm (Agilent Technologies LDA UK 
Limited, Lakeside, UK) was applied for separation. A 9 min gradient UPLC 
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condition was used from 10% to 90% mobile phase B for 4 min, equilibrated at 90% 
B for 1.5min, followed by 0.1 min gradient from 90% to 10% B and held at 10% B 
for another 3.4min with the mobile phases consisted of A: PFOA (1g) in 0.1% formic 
acid, 95% ACN, 5% H2O and B: PFOA (1g) in 0.1% formic acid, 95% H2O, 5% 
ACN. The coupled MS was operated at positive ion electrospray mode. 
The percentages of drug metabolized were calculated using the Microsoft Excel 
software and the data were plotted into a bar chart using GraphPad Prism 6. 
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Scheme 1  Synthetic routes for 8a and 8b 
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Scheme 2  Synthetic route for 9b  
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Table 1 Physicochemical parameters for 3-hydroxypyridin-4-ones. 
Compound  pKa1 pKa2 logK1 logβ2 logβ3 pFe3+ logP(ligand) logP(iron complex) 
Deferiprone (1) 3.61 9.78 15.03 27.42 37.35 20.74 -0.77 -2.60 
(8a) 3.31 9.34 14.34 26.22 35.76 20.46 -0.93 -2.69 
(9a) 3.64 9.13 13.96 25.62 35.07 20.39 -1.19 -3.63 
(10a) 3.37 10.32 15.51 28.12 37.93 19.71 -0.51 -1.86 
(7) 3.64 9.73 14.79 26.96 36.63 20.17 -0.58 -2.46 
(8b) 3.31 9.49 14.41 26.31 35.80 20.06 -0.59 -2.03 
(9b) 3.60 9.32 14.18 25.92 35.37 20.13 -0.73 -2.00 
(10b) 3.43 10.27 15.35 27.75 37.28 19.22 -0.13 -1.08 
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Figure Legends  
 
Figure 1. Spectrophotometric titration of 3-hydroxy-5-methyl-4(1H)-pyridone (8b). 
A, titration of free ligand (8b) over the range pH 1.6-11.0; B, titration of (8b) in the 
presence of iron(III) (5:1, molar ratio) over the range pH 1.2-8.0; C, speciation plot 
of iron(III)·8b complexes; [FeIII] = 1µM; [8b] = 10µM. 
 
Figure 2. Relationship between logD values (pH 7.4) of free ligands and their 
corresponding (3:1) iron(III) complexes. 
 
Figure 3. Percentage contribution of zwitterionic mesomers (23) for 
3-hydroxypyridin-4-ones; □,in vacuo; ■, in water. 
 
Figure 4. ESI mass spectrum of deferiprone (1) presented as aqueous solution (pH 
7.4, 140µM); dimer, 279.0; monomer, 140.17. 
 
Figure 5. Influence of hydroxypyridin-4-one concentration on dimerisation. 
Dimerisation recorded by peak height ratio of species in mass spectra. 
 
Figure 6. Metabolic conversion of 3-hydroxypyridin-4-ones by human liver 
microsomes; black bar: phase 1 metabolism; grey bar: phase 1 and phase 2 
metabolism 
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